sebra-shutterstock-com-court-gavel--1
9 January 2017Americas

Sanofi and Regeneron to appeal against Praluent injunction

Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent (alirocumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.

More on this story

Americas
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.

More on this story

Americas
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.